Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VICD Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency
NCT04240054Phase 2Recruiting
- Sponsor
- Medical College of Wisconsin
- Start
- Nov 2021
- Primary completion
- Dec 2029
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of isatuximab in multiple myeloma (MM) (2 cohorts), sponsored by Medical College of Wisconsin. Primary endpoint: Very Good Partial Response. Started Nov 2021; status: recruiting.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04240054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04240054.